Daxor (DXR) vs Xtant Medical (XTNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Daxor (DXR) has outperformed Xtant Medical (XTNT) over the past year, losing 43.5% versus a loss of 66.1%. Over five years, DXR leads with a -32.3% price change compared with -73.1% for XTNT. Daxor is the larger company by market cap ($43.5 million vs $29.5 million), about 1.5 times the size, while Xtant Medical is growing revenue faster (+14.2% vs -8.4%).
Xtant Medical converts more of its revenue into profit, with a net margin of 3.7% versus -496.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | XTNT |
|---|---|---|
| Share price | $7.45 | $0.21 |
| Market cap | $43.49M | $29.49M |
| 1-day change | -7.33% | -2.82% |
| YTD return | -49.49% | -73.08% |
| 1-year return | -43.52% | -66.13% |
| 5-year return | -32.27% | -73.08% |
| P/E ratio (TTM) | 6.77 | — |
| EPS (TTM) | $1.10 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.45M | $133.93M |
| Revenue growth (YoY) | -8.42% | +14.21% |
| Net income (latest FY) | $-7.19M | $4.97M |
| Gross margin | 54.89% | 62.92% |
| Operating margin | -400.07% | 5.44% |
| Net margin | -496.81% | 3.71% |
| 52-week high | $14.76 | $0.84 |
| 52-week low | $6.94 | $0.17 |
| Distance from 52-week high | -49.53% | -75.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +168.46% | +390.48% |
| Average volume | 22.43K | 1.69M |
| Shares outstanding | 5.84M | 140.45M |
| Employees | — | 151 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXR has outperformed XTNT by 22.6 percentage points over the past year.
- Xtant Medical is more profitable, keeping 3.7 cents of every revenue dollar as net income versus -496.8 cents for Daxor.
- Xtant Medical grew revenue faster in its latest fiscal year (+14.21% vs -8.42%).
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About Xtant Medical
XTNT stock →Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.
Health Care · Medical/Dental Instruments · 151 employees
DXR vs XTNT FAQ
Which is bigger, Daxor or Xtant Medical?
Daxor (DXR) is larger, with a market capitalization of $43.49M compared with $29.49M for Xtant Medical (XTNT).
Which stock has performed better over the past year, DXR or XTNT?
DXR returned -43.52% over the past 12 months, compared with -66.13% for XTNT (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and Xtant Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.